ERTC Members

Initiated in 2004, the EURORDIS Round Table of Companies (ERTC) is a “club” of pharmaceutical companies with a common interest in rare diseases and orphan drug development.

Members agree to financially support EURORDIS activities and benefit from the development of a fruitful exchange between EURORDIS itself, government and regulatory authorities, academics and patients representatives. These exchanges mainly take place at closed bi-annual ERTC Workshops. Three levels of membership exist -Sapphire, Emerald and Ruby - the last one corresponding to the largest financial contribution.

Companies interested in the challenging field of rare disease are invited to become members of the EURORDIS Round Table of Companies. More about ERTC membership

2012 Members

• Ruby Members
       
Celgene Pfizer Sigma-Tau  
• Emerald Members
     
Aegerion Alexion Pharmaceuticals Inc. Baxter Bayer Schering Pharma AG Biomarin
CLS Behring Genzyme GRIFOLS GlaxoSmithKline LFB
Medunik Canada Novartis Pharmaceuticals Orphan Europe Shire Pharmaceuticals, Inc Swedish Orphan International
Takeda Pharmaceuticals Europe Ltd. ViroPharma Europe
• Sapphire Members
     
Actelion Website Amgen Amicus Therapeutics ARIAD Pharmaceuticals, Inc. Biogen Idec
Chiesi Farmaceutici SpA Clovis Oncology Inc. Dompé Group Généthon InterMune, Inc.
Janssen R&D US Lysogene-Q Mark Krueger & Associates  Inc. Merck Serono International PharmaMar
PTC Therapeutics Rare Partners Synageva BioPharma

 

 

 

* In-Kind member acting as liaison with NORD Corporate Council in the US and in recognition of support of the ERTC workshop dinners


Disclaimer
EURORDIS is not responsible for any content of other websites accessible from this page, nor does it endorse or in any respect warrant any third party products or services by virtue of any information, material or content referred to or included on, or linked from or to the EURORDIS website. EURORDIS does not endorse medicinal products, brands or health services.

 


Author: EURORDIS

 

Page created: 19/08/2009
Page last updated: 26/04/2012